Bruker (BRKR) Stock
Global scientific instrument maker for research and diagnostics. Here's the price, business snapshot, and what's worth knowing about Bruker in October 2026.
Bruker Corporation (BRKR) is a US-headquartered maker of scientific instruments used in life sciences, materials research and diagnostics. Its product mix includes mass spectrometers, nuclear magnetic resonance (NMR) systems, X-ray diffraction and imaging platforms, and related consumables and service contracts. With a market capitalisation near $5.9 billion, Bruker sits in the small‑to‑mid cap segment where growth can be driven by R&D spending, academic and pharmaceutical investment, and demand for advanced analytical tools. Strengths include a diversified technology base, recurring service and consumable revenues, and a global sales footprint. Key risks are capital‑equipment cyclicality, competition from larger instrument groups, exposure to currency and supply‑chain pressures, and the need for sustained R&D investment. Investors should treat Bruker as a growth‑oriented industrial/scientific instruments play and note that returns are not guaranteed; values can fall as well as rise. This is general educational information, not personalised investment advice.
Bruker (BRKR) Stock Forecast
Analyst price target, next 12 months
$68.95
+9.0% vs today's $63.24
Price range over the last 12 months
Close to its 12-month high
Analysts covering Bruker have a consensus 12-month target of $68.95, above the current price of $63.24.
Analyst targets are opinions, not guarantees. Capital at risk. Data as of 4 Oct 2026.
Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Bruker Corporation's stock with a target price of $68.95, indicating growth potential.
Financial Health
Bruker Corporation is performing well with strong revenue and cash generation, indicating solid business health.
Dividend
Bruker Corporation's low dividend yield of 0.32% means it's not ideal for income-focused investors. If you invested $1000 you would be paid $3.20 a year in dividends (based on the last 12 months).
Why You’ll Want to Watch This Stock
Recurring Revenue Engine
Service contracts and consumables provide a steady income stream that can temper equipment‑sale cyclicality, though performance can vary with customer investment cycles.
Global R&D Exposure
Bruker benefits from demand across academia, pharma and industry worldwide, but is exposed to FX, regional funding shifts and supply‑chain risks.
Innovation and Competition
Sustained R&D and selective acquisitions drive product differentiation, while competition from larger instrument groups and the need for capital investment remain ongoing challenges.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
